TIGIT and non-small cell lung carcinoma: In a phase II trial of patients with advanced PD-L1+ NSCLC, tiragolumab (anti-TIGIT) plus atezolizumab (anti-PD-L1) treatment demonstrated significant improvement compared to atezolizumab monotherapy (ORR, 37.3% vs. 20.5%; mPFS, 5.6 vs. 3.9 months).